Brain insulin resistance and brain health in people with diabetes
Official title: Disentangling the Effect of Brain Insulin Resistance on Brain Health (BIR-BrainHealth)
Run by Copenhagen University Hospital, Rigshospitalet · NCT07374705 · Data updated 2026-11-12
This project will test whether brains that don't respond well to insulin in people aged 50–80 with type 1 or type 2 diabetes are linked to worse thinking and structural brain changes compared with people without diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Copenhagen University Hospital, Rigshospitalet Academic / other |
| Locations | 3 sites (Glostrup Municipality and 2 other locations) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | October 2031 |
| Study ends | January 2032 |
| Registry record updated | February 25, 2026 |
| Trial ID | NCT07374705 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 50–80 with type 1 diabetes for at least 10 years or type 2 diabetes for at least 5 years who do not have dementia and meet the trial's safety and MRI eligibility criteria.
✕Probably not a fit
People with diagnosed dementia, recent major stroke, active recent cancer, uncontrolled psychiatric illness, severe sensory impairment, weight over 140 kg, or who cannot pause certain medications are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The multicenter project uses cognitive testing, advanced MRI scans, metabolic profiling, and multi-omics to explore whether brain insulin resistance (BIR) and cerebrovascular damage explain cognitive decline in diabetes. This registration covers the MRI components; PET imaging is not included here. The study plans to enroll about 50 people with type 1 diabetes, 50 with type 2 diabetes, and 50 control participants across sites in Denmark and Germany. Participants will be aged 50–80 and meet prespecified diabetes duration and safety criteria.
Why it matters
Potential benefit: If successful, the work could help identify patients at higher risk of cognitive decline and point to new prevention or treatment targets for diabetes-related brain problems.
How similar studies have gone: Smaller prior studies have suggested a link between brain insulin resistance and cognitive decline, but no large MRI-focused multicenter studies have yet confirmed this relationship.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (all): * age 50-80 years Inclusion Criteria (diabetes only): * Diagnosis of either type 1 diabetes or type 2 diabetes * Diabetes duration of ≥10 years for individuals with type 1 diabetes and ≥5 years for individuals with type 2 diabetes Exclusion Criteria: * HbA1c \>100 mmol/mol * Other type of diabetes * Weight \>140 Kg * Treatment with drugs that cannot be paused for 12 hours * Diagnosis of dementia * Active and recent (1year) malignant disease * History of major stroke * Major depression and/or treatment with antipsychotics * History of traumatic brain injury * Other medical condition or disorder (e.g., epilepsy, recent concussion) that in the opinion of the investigator precludes compliance with the protocol, evaluation of the results or represent an unacceptable risk for the participant's safety. * Inability to perform neuropsychological tests (e.g., severe vision and hearing impairment that cannot be improved with aids such as glasses and hearing aids, or language barrier.) * Severe claustrophobia * Foreign bodies of metal in the body which prohibits brain MRI scans (e.g. pacemaker or screws/plates from surgery in the head or neck region) * Participants who do not wish to be informed about accidental findings by MRI * eGFR measurement \<45 within 3 months of study visit
Where it's running
-
Rigshospitalet
Glostrup Municipality, Denmark Recruiting -
Steno Diabetes Center Copenhagen
Herlev, Denmark Recruiting -
University of Ulm
Ulm, Germany Recruiting
Study contacts
- Principal investigator: Henrik BW Larsson, Professor — Copenhagen University Hospital, Rigshospitalet
- Study coordinator: Henrik BW Larsson, Professor
- Email: henrik.bo.wiberg.larsson@regionh.dk
- Phone: +45 24824294
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remote-patient monitoring in diabetes care shows real-world outcomes
A real-world, pre-post observational study at Steno Diabetes Center Copenhagen tests whether adding remote-patient-monitoring within the EHR can maintain glycemic outcomes over two years for about 12,000 people with diabetes compared with prior ambulatory care.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
See if short-term supervised resistance training improves muscle health and function in frail older adults with type 2 diabetes
This study tests whether a brief, supervised resistance training program can improve skeletal muscle health and physical function in frail adults over 65 who have type 2 diabetes.
-
Empagliflozin, Metformin, or both for muscle energy in adults with type 2 diabetes
This study tests whether empagliflozin, metformin, or their combination can improve skeletal muscle oxidative capacity and microvascular reactivity in adults recently diagnosed with type 2 diabetes.
-
Perioperative Meditation Music for Type 2 Diabetes Patients Undergoing Elective Surgery
We’re testing whether playing self-selected meditation music around surgery helps adults with type 2 diabetes stay calm, sleep better, and keep blood sugar steadier.
-
How metformin works in people with or without the SLC16A11 risk variant
This study tests whether the SLC16A11 genetic variant changes how adults with type 2 diabetes respond to metformin over 6 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.